Compare Regeneron Pharmaceuticals Inc (REGN) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Ryanair Holdings plc — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.15B), while Ryanair Holdings plc trades at $54.25 (market cap $27.24B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.1× Ryanair Holdings plc's market cap, and Ryanair Holdings plc pays the higher dividend (1.66%). Which is the better fit depends on your goals.
| REGN | RYAAY | |
|---|---|---|
Market Cap | $83.15B | $27.24B |
Sector | Health | Industrials |
52-Week High | $852.03 | $73.82 |
52-Week Low | $555.51 | $53.24 |
Enterprise Value | $77.86B | $24.19B |
Dividend Yield | 0.47% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% on the day, with a bullish technical signal from moving averages and a neutral RSI near 54. The stock shows strong profitability with a net income margin of 27.86% and consistent earnings beats in recent quarters. However, multiple class-action lawsuits filed in September 2026 allege securities fraud related to a Phase 3 clinical trial disclosure, creating near-term uncertainty.
The outlook remains cautiously optimistic given robust fundamentals and a 69% analyst buy rating, but legal overhangs and a projected earnings dip in 2026 pose risks. Upside hinges on legal resolution and pipeline execution, while downside is capped by institutional support like CalSTRS' recent $79 billion position increase.
RYAAY trades at $54.37, down 1.79% today, with bearish technical signals but strong fundamentals including 12.13% net margins and 22.41% ROE. Recent earnings show mixed results with a Q1 beat but Q2 miss, while Q3 expectations are high at $3.38 EPS. The company maintains robust cash flow from operations at $3.42B despite net cash flow turning negative in 2025. Analyst consensus remains positive with 62.5% buy ratings, though recent news highlights concerns about oil price exposure and reduced traffic forecasts.
The outlook balances strong profitability and market position against near-term headwinds from fuel costs and competitive pricing. Investment opportunity lies in Ryanair's industry-leading efficiency and potential market share gains during industry consolidation. Key risks include unhedged fuel costs, winter capacity cuts, and macroeconomic sensitivity. The stock's current valuation at 13.04 P/E appears reasonable if the company can maintain its earnings trajectory amid industry challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
